ArticleClinical and translational radiation oncology2018
Prospective
Article in Clinical and translational radiation oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Transoral robotic surgery vs. non-robotic surgeries for oropharyngeal squamous cell carcinoma: systematic review and meta-analysis.Journal of robotic surgery · 2023Pooled it
- Clinical application of MR-Linac in tumor radiotherapy: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer.Radiation oncology (London, England) · 2025Trial
- Article
- Automated daily dose accumulation workflow for treatment quality assurance during online adaptive radiotherapy with a 0.35T MR-linac.Journal of applied clinical medical physics · 2025Article
- UMamba Adjustment: Advancing GTV Segmentation for Head and Neck Cancer in MRI-Guided RT with UMamba and NnU-Net ResEnc Planner.Head and Neck Tumor Segmentation for MR-Guided Applications : First MICCAI Challenge, HNTS-MRG 2024, held in conjunction with MICCAI 2024, Marrakesh, Morocco, October 17, 2024, proceedings · 2025Article
- Gradient Map-Assisted Head and Neck Tumor Segmentation: A Pre-RT to Mid-RT Approach in MRI-Guided Radiotherapy.Head and Neck Tumor Segmentation for MR-Guided Applications : First MICCAI Challenge, HNTS-MRG 2024, held in conjunction with MICCAI 2024, Marrakesh, Morocco, October 17, 2024, proceedings · 2025Article
- Conference Report: Review of Clinical Implementation of Advanced Quantitative Imaging Techniques for Personalized Radiotherapy.Tomography (Ann Arbor, Mich.) · 2024Article
- Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view.Cancer medicine · 2024Review
- Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation ofJournal of medical imaging (Bellingham, Wash.) · 2023Article
- Magnetic Resonance-Guided Radiation Therapy for Head and Neck Cancers.Current oncology (Toronto, Ont.) · 2022Review
- Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate.Radiation oncology (London, England) · 2022Article
- Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.CA: a cancer journal for clinicians · 2022Review
- Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation.Frontiers in oncology · 2022Review
- Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.International journal of radiation oncology, biology, physics · 2021Article
- [Magnetic-resonance-guided radiotherapy : The beginning of a new era in radiation oncology?]Der Radiologe · 2021Review
- MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges.Frontiers in oncology · 2021Article
- Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.The British journal of radiology · 2020Article
- MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?Frontiers in oncology · 2020Review
- Adaptive radiotherapy for head and neck cancer.Cancers of the head & neck · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 4 countries.
Funding
Abstract
purposeWe aim to determine the feasibility and dosimetric benefits of a novel MRI-guided IMRT dose-adaption strategy for human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPC). MATERIALS/
methodsPatients with locally advanced HPV+ OPC underwent pre-treatment and in-treatment MRIs every two weeks using RT immobilization setup. For each patient, two IMRT plans were created (i.e. standard and adaptive). The prescription dose for the standard plans was 2.12 Gy/fx for 33 fractions to the initial PTV. For adaptive plans, a new PTV
resultsFive patients were included in this pilot study, 3 men and 2 women. Median age was 58 years (range 45-69). Three tumors originated at the tonsillar fossa and two at the base of tongue. The average dose to 95% of initial PTV volume was 70.7 Gy (SD,0.3) for standard plans vs. 58.5 Gy (SD,2.0) for adaptive plans. The majority of OARs showed decrease in dosimetric parameters using adaptive plans vs. standard plans, particularly swallowing related structures. The average reduction in the probability of developing dysphagia ≥ grade2, feeding tube persistence at 6-month post-treatment and hypothyroidism at 1-year post-treatment was 11%, 4%, and 5%, respectively. The probability of xerostomia at 6-month was only reduced by 1% for adaptive plans vs. standard IMRT.
conclusionThese
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.